Cuba’s Centre for Genetic Engineering and Biotechnology (CIGB) highlights the value of Nasalferon, a drug with preventive, prophylactic and therapeutic use in acute respiratory infections.

Its use was officially documented in a Phase III Clinical Study, which was endorsed by the Cuban regulatory authority: the Centre for the State Control of Medicines, Equipment and Medical Devices.

This definitive registration was granted once the results of the clinical development demonstrated that this medication meets all the necessary requirements of quality, safety, efficacy and effectiveness.

The CIGB recalls on its Facebook social media profile that the drug already had a previous Conditional Health Registration, granted in 2024, for the prophylaxis of SARS-CoV-2 infection, the coronavirus that causes Covid-19.